Navigation Links
Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results
Date:11/13/2008

in patients with heart failure. Key

assessments include glomerular filtration rate, tubular function, renal

plasma flow, urine output and mean arterial pressure.

-- As of the third quarter of 2008, Nile announced interim data from its

Phase 2a Hemodynamic clinical study of CD-NP. Enrollment in the study

is ongoing. The primary objective of the study is to assess hemodynamic

effects of intravenous infusions of CD-NP in patients with heart

failure. Key assessments include measurement of pulmonary capillary

wedge pressure (PCWP), blood pressure and kidney function.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure; 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties; and CU-NP, a novel rationally designed natriuretic peptide. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of our product development, future financial position, future financial results, plans and objectives of management are forw
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
2. Cell Therapeutics, Inc. (CTI) Oppenheimer & Co. Healthcare Conference Presentation to be Webcast
3. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
4. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase Up to $18 Million of Senior Convertible Notes
5. Cell Therapeutics, Inc. Announces $12 Million Equity Line of Credit
6. Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc.
7. Zevalin Revenues Lead Cell Therapeutics, Inc.s First Quarter 2008 Financial Results
8. Juvaris BioTherapeutics, Inc. Announces the Appointment of Grant E. Pickering as Chief Executive Officer
9. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results
10. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Mutually Terminate Merger Agreement; Oracle Healthcare Acquisition Corp. Cancels Special Meeting
11. Cell Therapeutics, Inc. Announces Issuance of $51.7 Million of New 2012 Convertible Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Launches Orphan Drug Workshop at KGI 2Daniel K. Spiegelman Elected to Board of Directors of Omeros 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 3Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 4Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 5Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 6Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 7Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 8Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 9Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 10Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 11Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 12Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 13Cumberland Pharmaceuticals and Phebra Pty Ltd Sign Exclusive Agreement for Commercialization of Caldolor 28R 29 in Australia and New Zealand 5840 1Cumberland Pharmaceuticals and Phebra Pty Ltd Sign Exclusive Agreement for Commercialization of Caldolor 28R 29 in Australia and New Zealand 5840 2Cumberland Pharmaceuticals and Phebra Pty Ltd Sign Exclusive Agreement for Commercialization of Caldolor 28R 29 in Australia and New Zealand 5840 3Cumberland Pharmaceuticals and Phebra Pty Ltd Sign Exclusive Agreement for Commercialization of Caldolor 28R 29 in Australia and New Zealand 5840 4Cumberland Pharmaceuticals and Phebra Pty Ltd Sign Exclusive Agreement for Commercialization of Caldolor 28R 29 in Australia and New Zealand 5840 5Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 1Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 2Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 3Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 4Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 5Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 6Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 7Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 8Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 9Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 10Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 11Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 12Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 13Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 14Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 15Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 16Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 17Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 18Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 19Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 20Geneticists hunt for scleroderma triggers 60340 1Geneticists hunt for scleroderma triggers 60340 2